Minerva Neurosciences Inc
Company Profile
Business description
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Contact
1500 District Avenue
BurlingtonMA01803
USAT: +1 617 600-7373
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,148.90 | 93.60 | 1.16% |
| CAC 40 | 8,094.20 | 77.27 | -0.95% |
| DAX 40 | 22,999.15 | 288.91 | -1.24% |
| Dow JONES (US) | 41,953.32 | 11.31 | -0.03% |
| FTSE 100 | 8,701.99 | 4.67 | -0.05% |
| HKSE | 24,219.95 | 551.19 | -2.23% |
| NASDAQ | 17,691.63 | 59.16 | -0.33% |
| Nikkei 225 | 37,751.88 | 93.54 | -0.25% |
| NZX 50 Index | 12,054.72 | 8.79 | 0.07% |
| S&P 500 | 5,662.89 | 12.40 | -0.22% |
| S&P/ASX 200 | 7,918.90 | 90.60 | 1.16% |
| SSE Composite Index | 3,408.95 | 17.48 | -0.51% |